TrialCNS drugs2025

Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled Trial.

Stuart Madden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.